<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147778">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176617</url>
  </required_header>
  <id_info>
    <org_study_id>UPenn811675</org_study_id>
    <nct_id>NCT01176617</nct_id>
  </id_info>
  <brief_title>Assessing Arrhythmias After Ablation Using Implantable Recorders</brief_title>
  <acronym>ABACUS</acronym>
  <official_title>Assessment of Arrhythmia Burden in Patients Undergoing Atrial Fibrillation Using an Implantable Loop Recorder (ILR) Versus Conventional Monitoring Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if continuous monitoring using an implantable loop
      recorder (ie. a device that is placed just underneath the skin of the chest and monitors the
      heart rate and rhythm) for a year long period after atrial fibrillation ablation may be
      superior to the current conventional monitoring strategy used by us for determination of
      atrial fibrillation recurrence (ie. return of the abnormal heart rhythm) and/or arrythmia
      burden (ie. how long the abnormal rhythm continues or how often the rhythm occurs). Some
      data suggests that continuous monitoring over longer periods may be better in identifying
      recurrence of atrial fibrillation after ablation and thus assist in its overall management.
      The device being used for this study is the Reveal XT, which, is currently FDA approved for
      monitoring all varieties of cardiac rhythm disorders including atrial fibrillation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arrhythmia Burden</measure>
    <time_frame>12 months</time_frame>
    <description>The primary outcome will be arrhythmia burden (atrial fibrillation and/or other atrial arrhythmias) after atrial fibrillation ablation over the initial 6 months and one year post-ablation as detected by the implantable loop recorder versus the conventional monitoring strategy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of actionable events resulting in change of clinical care</measure>
    <time_frame>12 months</time_frame>
    <description>Change of clinical care include initiation of previously discontinued and/or new anti-arrhythmic drugs, decision for repeat ablation, hospitalization for arrhythmias, discontinuation or reinitiation of atrio-ventricular nodal blocking agents, discontinuation or reinitiation af anticoagulation after ablation and/or decision to implant a pacemaker and/or defibrillator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measures</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life measures will be achieved using the visual analog scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Conventional Monitoring Strategy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will be monitored for 12 months using the conventional strategy which includes wearing a monitor over 3 separate 30-day periods over the first year post-ablation and daily pulse checks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reveal XT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will be monitored using the conventional monitoring strategy for the first 6 months post-ablation. During the next 6 months, subjects will be monitored using the data from the Reveal device, transmitted from home every 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reveal XT implantable loop recorder</intervention_name>
    <description>All study participants will receive the Reveal XT implantable loop recorder immediately after completion of the ablation procedure.</description>
    <arm_group_label>Reveal XT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than 18 years

          -  Undergoing ablation for atrial fibrillation at the University of Pennsylvania

        Exclusion Criteria:

          -  Patients with already implanted devices, including pacemakers, implantable cardiac
             defibrillators and cardiac resynchronization devices
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Dixit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <lastchanged_date>August 14, 2014</lastchanged_date>
  <firstreceived_date>August 4, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>A-Fib</keyword>
  <keyword>AF</keyword>
  <keyword>Persistent</keyword>
  <keyword>Permanent</keyword>
  <keyword>Pulmonary Vein isolation</keyword>
  <keyword>Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
